Biotechnology startup Reveal Genomics SL said that a study, published in Nature Communication, found its machine learning-based technology applied to circulating tumor DNA (ctDNA) is able to predict drug response and survival outcome in patients with metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitors.